An innovative asthma treatment developed by Chippenham-based specialist pharmaceutical firm Vectura is to go on sale in the US in deal that could earn it more than $1m. Under the licensing agreement announced this week, the VR730 product – which uses Vectura’s groundbreaking dry powder inhalation technology – is to be manufactured and commercialised...